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Abstract
Introduction: In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL
+ clone
and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived
from the BCR-ABL
+ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is
known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders.
Case presentation: We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by
chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib.
Conclusion: This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL
+ chronic myeloid
leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future
studies using imatinib to treat patients with chronic myeloid leukemia.
Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproli-
ferative disorder that results from the malignant
transformation of a hematopoietic stem cell. It is char-
acterized by the Philadelphia chromosome (Ph), which
is formed by translocation and fusion of the long arms
of chromosomes 9 and 22 in a pluripotent hematopoie-
tic progenitor cell. At the molecular level, the fusion
generates a BCR-ABL protein with constitutive tyrosine
kinase activity. Tyrosine kinase inhibitors such as imati-
nib are able to suppress the BCR-ABL
+ clone and induce
molecular remission. Megakaryocytes are thought to
belong to the BCR-ABL
+ clone, and abnormal platelet
function has been described in CML. However, little is
known about the influence of modern targeted therapy
on CML-associated platelet disorders. We report
the case of a massive hemorrhage caused by CML-
associated platelet dysfunction which improved after
treatment with imatinib.
Case presentation
A 32-year-old Caucasian man consulted his primary
care physician because of left upper-quadrant abdominal
pain, dyspnea upon exertion, drenching night sweats,
and unintentional weight loss. His initial clinical
examination revealed tachycardia of 120 beats/minute,
pronounced pallor, and splenomegaly of 8 cm×26 cm.
Laboratory analysis showed a leukocyte count of
327×10
9/L, a hemoglobin level of 7.0 g/dL, and a plate-
let count of 377×10
9/μL. The patient’s lactate dehydro-
genase level was significantly elevated at 1080 IU/L. His
coagulation tests showed a normal activated partial
thromboplastin time (aPTT) of 34 seconds (< 36
seconds) and an international normalized ratio (INR) of
1.1. The patient was taking no medications.
He was immediately referred to our Department of
H e m a t o l o g ya n dO n c o l o g y .T h e r eab o n em a r r o w
aspiration was performed, and cytomorphologic as well
as cytogenetic analysis was carried out. Microscopic
examination showed a left-shifted granulopoiesis with
8% blasts and 20% promyelocytes. The alkaline phospha-
tase index was 2. A BCR-ABL fusion transcript (coeffi-
cient 26.074 = 100×bcr-abl/abl) could be identified by * Correspondence: michael.bergwelt@uk-koeln.de
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aP h
+ CML in chronic phase was made.
The patient initially underwent leukapheresis twice
and then received cytoreductive chemotherapy with
hydroxyurea. Simultaneously, the search for a bone
marrow donor was initiated. After 14 days, normal
leukocyte counts were reached and the therapeutic regi-
men was switched to the tyrosine kinase inhibitor imati-
nib. While the initial management efficiently led to a
reduction of CML blasts, the patient encountered a
severe complication of a standard diagnostic procedure:
three days after bone marrow aspiration at the left
superior posterior iliac spine he complained about mas-
sive pain in his left buttock. A clinical examination
revealed massive swelling that was extremely tender to
touch. The increasing pain necessitated the use of con-
tinuous intravenous morphine. Computed tomography
revealed a large hematoma in the left gluteal region.
One day after the onset of symptoms surgery became
necessary because of increasing swelling accompanied
by a drop of the hemoglobin and impending compart-
ment syndrome. During surgery, diffuse bleeding was
noted without an identifiable lesion to major vessels or
other anatomic structures. The hematoma (about 500
mL) was evacuated, and fresh frozen plasma (FFP) as
well as packed red blood cells (PRBCs) were given to
the patient. At the time of surgery, PTT was 40
seconds, the INR was 1.4, and the platelet count was
300×10
9/L. The patient’s post-operative course was
complicated by continuous bleeding with a further
increase in size of the hematoma and extension into the
left leg, renewed deterioration of coagulation para-
meters, and onset of fever (< 38.5°C). Continuous sub-
stitution of FFP and PRBCs was necessary, and surgery
had to be repeated on day 9. Because of continuous
post-operative bleeding and the risk of compartment
syndrome, the wound was left open to reduce tissue
pressure. The bleeding time assessed according to the
modified template method was prolonged at 13 minutes.
Therefore, further platelet function tests were
performed. Occlusion times determined by using a pla-
telet function analyzer (PFA-100; Dade Behring, Inc.,
Deerfield, IL, USA) were 152 seconds for adenosine
diphosphate (ADP) (71 to 118 seconds) and > 300
seconds for collagen/epinephrine (C/Epi) (94 to 193
seconds), respectively. As the patient had no history of
bleeding prior to the diagnosis of CML, further labora-
tory examinations for other pathological bleeding
situations were not performed. Therefore, despite
increased platelet counts, platelet transfusions were
initiated. Following the platelet substitution, his bleeding
ceased quickly. The patient could be discharged 10 days
later. At that time, the patient had paresis of the leg
with a positive Trendelenburg’s sign due to compression
of the superior gluteal nerve. His bleeding time was still
highly pathologic upon discharge.
We assumed that the patient’s platelet dysfunction
originated from a clonal expansion of dysfunctional
megakaryocytes derived from the identical stem cell
from which the CML blasts had originated. We there-
fore hypothesized that treatment targeting BCR-ABL
would be equally effective in reducing the CML blasts
and dysfunctional megakaryocytes. Despite the risk of
hemorrhage in this patient, we therefore continued a
single-agent treatment strategy with imatinib in an out-
patient setting.
No further episodes of bleeding occurred during the
follow-up of the patient. During that time, the patient
underwent dental surgery without experiencing exces-
sive bleeding. The defect in the gluteal region disap-
peared completely as a result of secondary wound
healing, and the paresis regressed steadily. Six months
after discharge from the hospital the patient was in
excellent health. At his last complete laboratory follow-
up four years later, his bleeding time was normal (four
minutes) and his C/Epi occlusion time was 211 (94 to
193 seconds). He was in complete molecular remission.
Six years after the incident the patient remains clinically
in very good health without any signs of bleeding and
continues to be in complete molecular remission.
Discussion
The pathologic changes in CML affect not only CML
blasts but also other hematopoietic lineages, which adds
to the array of clinical manifestations and increases
morbidity as well as mortality of the disease [1-4].
Bleeding is a frequent complication in patients with
myeloproliferative disorders, including CML, and quali-
tative platelet abnormalities are frequently observed [5].
Thrombocytosis is observed in about one of three
patients, and platelet dysfunction occurs in one of six
patients. Platelet dysfunction in chronic myeloprolifera-
tive disorders is multi-factorial [6]. One of the most
characteristic platelet defects in myeloproliferative
disorders is a reduced responsiveness to epinephrine,
while the response to ADP usually is intact. This was
found to be due to a reduction in a-adrenergic recep-
tors on the platelet membrane. The cause of the
decreased surface expression of a-adrenergic receptors
is unknown, though.
Molecularly, BCR-ABL rearrangements have clearly
been demonstrated in megakaryocytic cell lines as well
as in megakaryocytes from the vast majority of CML
patients [1,3,4,7]. Therapeutic approaches in Ph
+ CML
to reduce the number of CML blasts previously had
proven effective in reducing the number of BCR-ABL
+
megakaryocytes [3,7]. Furthermore, previous studies in
which imatinib was used to treat patients with CML
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+ subpopu-
lations. Importantly, bone marrow biopsies in these
patients demonstrated an inhibitory effect of imatinib
on increased megakaryopoeisis [8]. Also, Thiele et al.[ 9 ]
found that the atypical micromegakaryocytes that are
prevalent in Ph
+ CML were significantly reduced after
imatinib therapy with a further reappearance of normal-
sized megakaryocytes.
The study by Nolte et al. [10] showed that not only
the transforming event but also the Ph
+ translocation
leading to BCR-ABL
+ fusion happens prior to the
differentiation of the pluripotent stem cell into different
myeloid lineages.
In vitro s t u d i e sd o n eb yE r a[ 1 1 ]a n dB u e tet al. [12]
showed two novel aspects of the differentiation of hema-
topoietic stem cells. Era demonstrated that enforced
BCR-ABL
+ expression was sufficient to increase the
number of both multi-lineage progenitors and myeloid
progenitors. Buet et al. showed that alteration of signal
transduction via BCR-ABL
+ reprograms megakaryocyte
cells into erythroid cells by down-regulation of FLI-1.
This suggests that BCR-ABL
+ represents a “molecular
switch” for the decision for growth and differentiation in
hematopoietic stem cells in general [12].
On the basis of the high frequency of megakaryocyte
involvement in CML patients and the concurrent
thrombocytosis in our patient, we assumed that platelet
dysfunction was a manifestation of CML and that the
megakaryocytes also carried the BCR-ABL fusion gene.
Interestingly, in our patient, the achievement of
complete molecular remission was paralleled by a signif-
icant improvement in platelet dysfunction (Figure 1).
This was reflected in normalization of bleeding time, a
decrease in C/Epi from > 300 seconds to 211 seconds,
and successful dental surgery without bleeding
complications.
Because of the patient’s clinical course and his reluc-
tance, we decided not to perform another bone marrow
biopsy to confirm BCR-ABL fusion transcripts in his
megakaryocytes.
Conclusion
T oo u rk n o w l e d g e ,t h i si st h ef i r s tr e p o r tt os h o wt h a t
platelet dysfunction and bleeding disorder in BCR-ABL
+
CML can be treated successfully with imatinib. To vali-
date these observations, we strongly suggest monitoring
platelet function in future studies using imatinib or sec-
ond-generation tyrosine kinase inhibitors, such as
Figure 1 Time course of platelet counts, leukocyte counts, quantitative polymerase chain reaction for BCR-ABL (expressed as log
reduction from baseline), and platelet function analyzer PFA-100 platelet function tests.
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for further research to validate our clinical observations.
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